Myovant Sciences Ltd Revenue Growth Rates (MYOV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Myovant Sciences Ltd   (NYSE: MYOV)
 

MYOV's Revenue Growth by Quarter and Year

Myovant Sciences Ltd 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MYOV Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter March -
3rd Quarter December 100.23
2nd Quarter September 104.82
1st Quarter June 116.49
FY 321.54





MYOV Revenue third quarter 2023 Y/Y Growth Comment
Myovant Sciences Ltd reported Revenue surge of 84.11% year on year in the third quarter 2023, to $ 100.23 millions, this is lower than Myovant Sciences Ltd 's recent average Revenue surge of 717.88%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 57 other companies have achieved higher Revenue growth. While Myovant Sciences Ltd ' s Revenue jump of 84.11% ranks overall at the positon no. 349 in the third quarter 2023.


MYOV Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter March - 133.93 % - -
3rd Quarter December 84.11 % 3844.93 % - -
2nd Quarter September 34.56 % - - -
1st Quarter June 183.71 % 23.19 % - -
FY   - 289.36 % - -

Financial Statements
Myovant Sciences Ltd 's third quarter 2023 Revenue $ 100.23 millions MYOV's Income Statement
Myovant Sciences Ltd 's third quarter 2022 Revenue $ 54.44 millions Quarterly MYOV's Income Statement


MYOV Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter March - 5.75 % 1683.33 % -
3rd Quarter December -4.38 % -30.12 % - -
2nd Quarter September -10.02 % 89.72 % - -
1st Quarter June 102.34 % 66.84 % - -
FY (Year on Year)   - 289.36 % - -


Back to MYOV Growth rate Comparisons >> Back to MYOV Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #96
Overall #349

Revenue Y/Y Growth Statistics
High Average Low
3847.79 % 717.88 % 23.19 %
(Dec 31 2021)   (Jun 30 2021)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #96
Overall #349
Revenue Y/Y Growth Statistics
High Average Low
3847.79 % 717.88 % 23.19 %
(Dec 31 2021)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Myovant Sciences Ltd 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1684.26 % 200.49 % -100 %
(Mar 31 2021)  


MYOV's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Myovant Sciences Ltd disclosed fall in Revenue from the second quarter by -4.38% to $ 100.23 millions, from $ 104.82 millions achived in the previous reporting period.

But that's not important problem, as Myovant Sciences Ltd 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 200 other companies have achieved higher Revenue quarter on quarter growth. While Myovant Sciences Ltd 's Revenue growth quarter on quarter, overall rank is 2902.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #201
Healthcare Sector #512
Overall #2902
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #201
Healthcare Sector #512
Overall #2902
Revenue Q/Q Growth Statistics
High Average Low
1684.26 % 200.49 % -100 %
(Mar 31 2021)  


MYOV's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Myovant Sciences Ltd disclosed fall in Revenue from the second quarter by -4.38% to $ 100.23 millions, from $ 104.82 millions achived in the previous reporting period.

But that's not important problem, as Myovant Sciences Ltd 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 200 other companies have achieved higher Revenue quarter on quarter growth. While Myovant Sciences Ltd 's Revenue growth quarter on quarter, overall rank is 2902.


Myovant Sciences Ltd 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 379.11 $ 333.32 $ 306.40 $ 230.97 $ 198.01
Y / Y Revenue Growth (TTM) 91.46 % 129.96 % - - -
Year on Year Revenue Growth Overall Ranking # 199 # 9 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 13.74 % 8.79 % 32.66 % 16.65 % 36.61 %
Seq. Revenue Growth (TTM) Overall Ranking # 826 # 32 # 30 # 422 # 803


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2022 period, Myovant Sciences Ltd 's cumulative twelve months Revenue were $ 379 millions, company would post below average annual Revenue growth of 36.61% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Myovant Sciences Ltd 's Revenue growth from the 104.82% growth in Sep 30 2022.

In the Healthcare sector 52 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 9 to 199.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 68
Healthcare Sector # 53
Overall # 199

Revenue TTM Y/Y Growth Statistics
High Average Low
129.96 %
 110.71 %
91.46 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 68
Sector # 144
S&P 500 # 826
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2022 period, Myovant Sciences Ltd 's cumulative twelve months Revenue were $ 379 millions, company would post below average annual Revenue growth of 91.46% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Myovant Sciences Ltd 's Revenue growth from the 104.82% growth in Sep 30 2022.

In the Healthcare sector 52 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 9 to 199.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 68
Healthcare Sector # 53
Overall # 199

Revenue TTM Y/Y Growth Statistics
High Average Low
129.96 %
110.71 %
91.46 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 68
Sector # 144
S&P 500 # 826




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MYOV's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Babylon Holdings Limited145.73%$ 145.729 millions
Luna Innovations Inc144.83%$ 144.833 millions
Repare Therapeutics Inc 144.82%$ 144.816 millions
Paratek Pharmaceuticals Inc 137.63%$ 137.631 millions
Dyadic International Inc 137.39%$ 137.392 millions
Procept Biorobotics Corporation134.53%$ 134.533 millions
Igc Pharma Inc 133.80%$ 133.803 millions
Innate Pharma Sa133.47%$ 133.470 millions
Lumos Pharma Inc 132.73%$ 132.727 millions
Collegium Pharmaceutical Inc 131.23%$ 131.229 millions
Arrowhead Pharmaceuticals Inc 127.95%$ 127.946 millions
Evoke Pharma Inc 120.86%$ 120.864 millions
Sanara Medtech Inc 117.76%$ 117.765 millions
Effector Therapeutics Inc 117.04%$ 117.042 millions
Rayont Inc 110.48%$ 110.484 millions
Kyntra Bio Inc 107.74%$ 107.737 millions
Lantheus Holdings Inc 103.12%$ 103.120 millions
Hookipa Pharma inc 100.98%$ 100.976 millions
Intelligent Bio Solutions Inc 100.62%$ 100.617 millions
Lexicon Pharmaceuticals Inc 100.00%$ 100.000 millions
Orgenesis Inc 97.68%$ 97.678 millions
Hims and Hers Health Inc 97.41%$ 97.408 millions
Emmaus Life Sciences Inc 96.36%$ 96.358 millions
Cvrx inc 96.17%$ 96.173 millions
Arbutus Biopharma Corp94.79%$ 94.791 millions
Pear Therapeutics Inc 94.32%$ 94.318 millions
Orasure Technologies Inc93.62%$ 93.616 millions
Pressure Biosciences Inc 92.63%$ 92.632 millions
Revance Therapeutics Inc 92.37%$ 92.374 millions
Rxsight Inc 90.93%$ 90.933 millions


About Myovant Sciences Ltd Revenue Growth Rates (MYOV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Myovant Sciences Ltd (CIK 1679082).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001679082-23-000025
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Myovant Sciences Ltd ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.